Pinetree Therapeutics Raises $47 Million in Oversubscribed Series B to Advance Next-Generation Protein Degraders in Oncology

Pinetree Therapeutics Closes $17 Million in Series A Funding to Advance AbReptor™ Protein Degradation Platform and Portfolio Programs

Pinetree Therapeutics Announces Exclusive Option and Global License Agreement for Preclinical EGFR Degrader Candidate with AstraZeneca

PineTree Therapeutics, Inc. Secures $23.5 Million of Series A1 Funding to Develop Cutting Edge Platform Technology to Create Therapeutic Assets for Unmet Medical Needs